Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422649 | 0.71 | BTK (0.44) | GUSBMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3027900 | 0.71 | GAA (0.38) | — | |
| SCHEMBL11155011 | 0.67 | RAB9A (0.50) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7652317 | 0.67 | KDM4E (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11169092 | 0.66 | AURKA (0.49) | GUSB | |
| SCHEMBL895 | 0.65 | GLA (0.37) | KMT2A | |
| SCHEMBL14877391 | 0.64 | MEN1 (0.46) | PIM1PIM3GABRA1GABRB2MEN1 | |
| SCHEMBL1256378 | 0.64 | KDM4C (0.35) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3103844 | 0.63 | — | — | |
| SCHEMBL1326990 | 0.63 | C5AR1 (0.38) | MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | PIM1 2790/4885PIM3 3177/4885GABRA1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.